Musings from The Power List: Piers Ingram
By Piers Ingram
October 20, 2026
Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines
4 min read
False
Advertisement
Power List
Musings From the Power List: Jason Bock
By Jason Bock
October 14, 2026
Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development
12 min read
The Staying Power of Small Molecules
October 8, 2026
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
4 min read
Musings from The Power List: Andres Sirulnik
By Andres Sirulnik
October 5, 2026
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
4 min read
The Resilience Prescription
October 2, 2026
We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and scientific uncertainty
5 min read
Development & Clinical
Cell & Gene
Interviews
Business & Trends
Technology & Manufacturing
Power List
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
3 min read
Musings from The Power List: Renee Aguiar-Lucander
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
Musings from The Power List: Michael May
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
The Power of Policy
September 17, 2026
What one policy change would accelerate progress in drug development and manufacturing? We asked the 2026 Power List.
8 min read
Musings from The Power List: Dajun Yang
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
